Last reviewed · How we verify
NCT04870073: RAPPER-MAN
Retrograde Autologous Priming and Mannitol for Reducing Hemodilution in Cardiac Surgery
Phase 3 trial testing Retrograde autologous priming in Hemodilution. Withdrawn.
21 September 2022
Quick facts
| Lead sponsor | Hamilton Health Sciences Corporation |
|---|---|
| Phase | Phase 3 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | factorial |
| Masking | single |
| Primary purpose | treatment |
| Start date | 21 September 2022 |
| Primary completion | 21 September 2022 |
| Estimated completion | 21 September 2022 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Retrograde autologous priming
- Mannitol (Mannitol) — full drug profile →
- Conventional Priming
Conditions studied
- Hemodilution — all drugs for Hemodilution →
- Coronary Artery Disease — all drugs for Coronary Artery Disease →
- Fluid Overload — all drugs for Fluid Overload →
Sponsor
Hamilton Health Sciences Corporation — full company profile →
Who can join
18 and older, any sex, with Hemodilution or Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Hemodilution reduces concentrations of blood constituents: concentration of hemoglobin, red blood cells (hematocrit), physiological ions and coagulation factors that can contribute to impaired hemostasis and increasing the risk of perioperative blood transfusions. This pilot study will assess the feasibility of a large RCT to evaluate 2 techniques for reducing hemodilution during cardiac surgery: 1) retrograde autologous priming and 2) intraoperative mannitol. The aim of this pilot trial is to demonstrate feasibility of a larger trial to evaluate whether retrograde autologous priming and/or mannitol are superior to conventional priming alone.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04870073
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Retrograde autologous priming
Trials testing the same drug.
- NCT04239677 — Impact of Retrograde Autologous Priming on the Coagulation Profile Assessed by Rotation Thromboelastometry (ROTEM) in Pa · NA · completed
Other recruiting trials for Hemodilution
Currently open trials in the same condition.
- NCT06399536 — Individualized ANH for Non-cardiac Surgery · NA · recruiting
- NCT05606536 — The Impact of Intra-operative Fluid Infusion Rate on Microcirculation · NA · recruiting
Other Hamilton Health Sciences Corporation trials
Trials by the same sponsor.
- NCT06567808 — Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over Trial · Phase 4 · not yet recruiting
- NCT07118696 — Evaluating a Shorter, Rifampicin-Based Treatment for People With Less Severe Tuberculosis Disease · Phase 3 · not yet recruiting
- NCT07027436 — Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Su · Phase 3 · not yet recruiting
- NCT06908694 — Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy · Phase 4 · recruiting
- NCT06836024 — A Trial of Actazin Versus PEG 3350 for Maintenance Therapy in Children With Constipation · Phase 2, PHASE3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04870073 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hamilton Health Sciences Corporation
- Last refreshed: 28 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04870073.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing